Quantitative cardiac amyloid radionuclide imaging

Robert J.H. Miller

doi:10.1016/j.nuclcard.2026.102724

Quantitative cardiac amyloid radionuclide imaging

2026-05-15

0

PRE

AI

DOI：10.1016/j.nuclcard.2026.102724

Original

Original request for help

Save

Abstract

En 中文

Cardiac amyloid radionuclide imaging (CARI) with single-photon emission computed tomography (SPECT) bone-avid tracers plays a key role in the noninvasive detection of transthyretin cardiac amyloidosis (CA). In addition, newer amyloid-binding tracers used with positron emission tomography (PET) can identify different types of CA. These SPECT and PET CARI techniques generate “hot-spot” images that represent tracer accumulation in regions of amyloid deposition and are typically interpreted visually by comparing myocardial uptake with reference regions such as bone or the blood pool. Although qualitative interpretation of SPECT CARI has been effective for diagnosis, it has notable limitations. This review focuses on methods for quantitative SPECT and PET CARI, emphasizing the need for standardization and its potential role in early detection of cardiac amyloidosis, evaluation of disease burden, risk prediction, and longitudinal monitoring of disease progression.

Keywords:

Quantitative cardiac amyloid radionuclide imaging

SPECT

PET

transthyretin cardiac amyloidosis

disease burden

Quantitative cardiac amyloid radionuclide imaging

Abstract

Journal

Organization